Therapeutic Potential of a Novel α
cell migration and invasion
epithelial-mesenchymal transition
stemness
triple-negative breast cancer
αvβ3 integrin
ψRGDechi
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
24 Jan 2019
24 Jan 2019
Historique:
received:
08
01
2019
revised:
17
01
2019
accepted:
20
01
2019
entrez:
27
1
2019
pubmed:
27
1
2019
medline:
27
1
2019
Statut:
epublish
Résumé
The mesenchymal sub-type of triple negative breast cancer (MES-TNBC) has a highly aggressive behavior and worse prognosis, due to its invasive and stem-like features, that correlate with metastatic dissemination and resistance to therapies. Furthermore, MES-TNBC is characterized by the expression of molecular markers related to the epithelial-to-mesenchymal transition (EMT) program and cancer stem cells (CSCs). The altered expression of α
Identifiants
pubmed: 30682838
pii: cancers11020139
doi: 10.3390/cancers11020139
pmc: PMC6406933
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
J Cell Biol. 1999 Nov 1;147(3):631-44
pubmed: 10545506
Pancreas. 2002 Aug;25(2):e30-5
pubmed: 12142752
Eur J Nucl Med Mol Imaging. 2004 Apr;31(4):521-7
pubmed: 14666386
Biochem Pharmacol. 2005 Nov 1;70(9):1277-87
pubmed: 16143315
Breast Cancer Res. 2006;8(2):R20
pubmed: 16608535
J Med Chem. 2006 Jun 1;49(11):3416-20
pubmed: 16722662
Nat Protoc. 2007;2(2):329-33
pubmed: 17406593
Clin Cancer Res. 2008 Aug 15;14(16):5209-19
pubmed: 18698039
Clin Cancer Res. 2009 Aug 15;15(16):5224-33
pubmed: 19671851
Stem Cells. 2010 Mar 31;28(3):390-8
pubmed: 19998373
J Transl Med. 2011 Jan 13;9:7
pubmed: 21232121
Theranostics. 2011;1:30-47
pubmed: 21544229
J Clin Invest. 2011 Jul;121(7):2750-67
pubmed: 21633166
J Nucl Med. 2012 Mar;53(3):443-50
pubmed: 22331221
Oncogene. 2013 Jan 31;32(5):544-53
pubmed: 22469978
Int J Oncol. 2013 Jan;42(1):83-92
pubmed: 23174862
Anticancer Res. 2013 Mar;33(3):871-9
pubmed: 23482756
Clin Cancer Res. 2013 May 15;19(10):2723-33
pubmed: 23549873
J Cell Mol Med. 2013 Aug;17(8):1038-47
pubmed: 23815612
Clin Cancer Res. 2013 Oct 1;19(19):5533-40
pubmed: 23948975
Nat Cell Biol. 2014 May;16(5):457-68
pubmed: 24747441
Oncologist. 2014 Jun;19(6):608-15
pubmed: 24794159
Clin Cancer Res. 2015 Apr 1;21(7):1688-98
pubmed: 25208879
PLoS One. 2014 Sep 23;9(9):e106441
pubmed: 25248000
Ann Diagn Pathol. 2014 Dec;18(6):343-50
pubmed: 25305804
Nature. 2015 Apr 16;520(7547):358-62
pubmed: 25855289
Cancer Res. 2015 Jun 1;75(11):2316-2325
pubmed: 25858145
Cancer Lett. 2016 Jan 1;370(1):100-7
pubmed: 26517945
Chemistry. 2016 Jan 11;22(2):681-93
pubmed: 26548575
Cell Death Dis. 2016 Apr 21;7:e2201
pubmed: 27100895
Nat Rev Clin Oncol. 2016 Nov;13(11):674-690
pubmed: 27184417
PLoS One. 2016 Jun 16;11(6):e0157368
pubmed: 27310713
Int J Mol Sci. 2016 Jul 11;17(7):
pubmed: 27409610
Nat Rev Clin Oncol. 2017 Oct;14(10):611-629
pubmed: 28397828
Sci Rep. 2017 Apr 20;7:46659
pubmed: 28425453
Cancers (Basel). 2017 Sep 04;9(9):null
pubmed: 28869579
Theranostics. 2017 Aug 22;7(14):3595-3607
pubmed: 28912898
Cancers (Basel). 2017 Sep 30;9(10):null
pubmed: 28974015
J Med Chem. 2017 Dec 14;60(23):9874-9884
pubmed: 29144748
J Clin Invest. 2018 Jan 2;128(1):531-544
pubmed: 29227280
J Exp Clin Cancer Res. 2018 Feb 09;37(1):23
pubmed: 29426357
Int J Cancer. 2018 Oct 15;143(8):1978-1993
pubmed: 29744876
Biomark Med. 2018 Jul;12(7):813-820
pubmed: 29902924
Nat Rev Cancer. 2018 Sep;18(9):533-548
pubmed: 30002479
Curr Med Sci. 2018 Jun;38(3):467-472
pubmed: 30074214
Mol Pharmacol. 2018 Dec;94(6):1334-1351
pubmed: 30262596
J Med Chem. 2018 Nov 8;61(21):9596-9610
pubmed: 30278131
Mol Oncol. 2019 Feb;13(2):228-245
pubmed: 30367545
Cancer Lett. 2019 Feb 1;442:320-332
pubmed: 30391782
Pharmaceuticals (Basel). 2018 Nov 13;11(4):null
pubmed: 30428522
Theranostics. 2018 Oct 6;8(18):5178-5199
pubmed: 30429893
Cell Adhes Commun. 1997 Mar;4(6):399-411
pubmed: 9177902